 In this prospective study, researchers examined the effectiveness of anti-illinois 5 biologics in treating severe asthma in Denmark. They found that 58% of patients treated with anti-illinois 5 biologics experienced a complete response within one year, meaning they were able to stop taking their medication and avoid asthma exacerbations and the need for systemic steroids. Patients who achieved a complete response also showed improved lung function and symptom control compared to those who did not. This suggests that anti-illinois 5 biologics are effective in treating severe asthma and can help patients achieve better health outcomes. This article was authored by Marianne Bastreps-Oindegarde, Suzanne Hansen and Sophie Durum and others.